Loading…
Glenmark Pharmaceuticals Limited's Goa manufacturing facility was cited for significant Current Good Manufacturing Practice (CGMP) violations in the production of finished pharmaceutical drugs, rendering products adulterated. The company failed to conduct thorough investigations into unexplained batch failures and out-of-specification results, particularly regarding 14 rejected batches of desmopressin acetate tablets (0.1mg and 0.2mg strengths) from 2018-2021 that showed content uniformity failures; despite attributing issues to undefined compression parameters, the firm failed to extend investigations to other batches, dosage strengths, and drug products to identify root causes. The inspection occurred May 12-20, 2022, with the FDA acknowledging the company's June 2022 response but determining that the violations were not adequately addressed.